SUBSCRIBE
SUBSCRIBE

Ipsen Biopharmaceuticals, Inc.

NEWS
Business
French Company Ipsen to Move U.S. Headquarters to Boston
It’s not exactly breaking news that in the U.S., the two top spots for biotech companies are Boston and San Francisco. But now there’s even more weight to that statement, as French company Ipsen announced it plans to relocate its U.S. operations from New Jersey to Kendall Square in Cambridge, Massachusetts. The announcement was made at the 2018 BIO International Convention in Boston.
June 8, 2018
 · 
3 min read
 · 
Mark Terry
Drug Development
Merrimack Pharmaceuticals Expands Phase II Lung Cancer Study
Merrimack Pharmaceuticals announced it is expanding enrollment in a Phase II lung cancer study.
March 12, 2018
 · 
2 min read
 · 
Alex Keown
Job Trends
Ipsen Preps To Go On Hiring Spree In Europe
July 28, 2017
 · 
1 min read
Tiny KalVista Explodes on $760 Million Deal With Drug Giant Merck & Co.
Business
Ipsen Agrees to Hire 100 Merrimack Employees Under $575 Million Cancer Deal
February 15, 2017
 · 
2 min read
Business
As Shire Closes on Baxalta, David Meek Takes the Helm at Ipsen
July 11, 2016
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Comeback Kid Exelixis Wrangles Cancer Deal Worth $855 Million with Ipsen
February 29, 2016
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Ipsen, Active Biotech AB Plummet As Prostate Cancer Drug Flunks Late-Stage Trial
April 16, 2015
 · 
2 min read
Mylan Inc., Theravance, Inc. Partner Up for $265 Million COPD Pact
Business
Ipsen Plants R&D Foothold in U.S. at New Mass. Facility
April 1, 2015
 · 
3 min read
Job Trends
Allergan Rival Ipsen to Continue U.S. Hiring Spree
March 13, 2015
 · 
3 min read
Load More
JOBS
IN THE PRESS
Policy
Health Canada Approves Ipsen’s Sohonos™ (palovarotene capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva
January 24, 2022
 · 
7 min read
Business
Ipsen Nominates Karen Witts as New Independent Board Member
January 21, 2022
 · 
6 min read
Business
Ipsen Delivers Strong Sales Growth for the First Nine Months and Improves Its Full-Year Guidance
October 21, 2021
 · 
16 min read
Drug Development
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3
October 18, 2021
 · 
8 min read
Ipsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer
September 18, 2021
 · 
19 min read
Policy
Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-submit Following Additional Data Analyses
August 13, 2021
 · 
11 min read
Business
Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
August 2, 2021
 · 
14 min read
ISPRM 2021: New Ipsen Analysis Highlights Potential Treatment Gap in Adults Living With Spasticity
June 11, 2021
 · 
10 min read
Ipsen Announces the Launch of an Employee Shareholding Plan
June 1, 2021
 · 
3 min read
Business
Ipsen Delivers Encouraging Sales Growth in the First Quarter of 2021 Despite the Pandemic, and Confirms Its Full-Year Guidance
April 22, 2021
 · 
14 min read
Load More